A Study of AZD0486 Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Inclusion Criteria:

1. Participant must be at least 18 years of age, inclusive, at the time of signing theICF.

2. Histologically confirmed diagnosis of FL Grades 1-3A per WHO 2016 classification

3. ECOG performance status of 0 to 2

4. No prior systemic lymphoma-directed therapy

5. Need for systemic treatment meeting at least 1 GELF criteria

6. FDG-avid and measurable disease

7. Adequate liver, hematological, renal and cardiac function.

The above is a summary, other inclusion criteria details may apply

Exclusion Criteria:

1. Follicular lymphoma Grade 3B (WHO 2016 classification) or suspicion for histologictransformation to high-grade/aggressive lymphoma

2. Contra-indication to BR, RCVP, and R-CHOP

3. Participants with or history of CNS lymphoma

4. Presence of >5000 circulating lymphoma cells

5. Active or uncontrolled infection requiring systemic therapy and which placesparticipant at unacceptable risk if he/she were to participate in the study

The above is a summary, other exclusion criteria details may apply